English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe Myeloma Research Institute’s launch follows many important accomplishments by C. Ola Landgren, M.D., Ph.D. and his team, who are dedicated to fulfilling a promise of providing the best cancer care to myeloma patients. Florida is among the states with the highest rates of new myeloma diagnoses in the U.S., with 7.9 cases diagnosed in every 100,000 of the state’s residents.
Tag: Ash
Fred Hutch at ASH: Global insights on AML outcomes, COVID-19 and cancer, CD19 CAR T-cell therapy updates, latest on precision oncology — and more
SEATTLE — Dec. 1, 2022 — The 64th Annual Meeting and Exposition of the American Society of Hematology (ASH) will take place virtually and in person Dec. 10-13 in New Orleans, Louisiana.
Dana-Farber President & CEO Emeritus receives ASH Award for Leadership in Promoting Diversity
Edward J. Benz, Jr., MD, President and CEO Emeritus of the Dana-Farber Cancer Institute and the Richard and Susan Smith Distinguished Professor at Harvard Medical School, has received the 2020 ASH Award for Leadership in Promoting Diversity.
Alleviating Confusion around Pain Management Recommendations
New information from NCCN, ASCO, ASH, CDC, FDA, and others seeks to provide clear guidance on how to optimally manage cancer-related pain without exacerbating the ongoing opioid crisis—published jointly in the Journal of the National Comprehensive Cancer Network and JCO Oncology Practice.
Lymphoma Patients May Have New Path to Remission, Even When CAR T Therapy Fails
A new, experimental immunotherapy can put patients with B-cell non-Hodgkin lymphoma (NHL) that is resistant to or has come back after multiple other therapies, including CAR T therapy, into remission.